~~<i id='EAA6265DC3'><strike id='EAA6265DC3'><tt id='EAA6265DC3'><pre id='EAA6265DC3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：hotspot 2025-09-06 04:38:14 - browse：832

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Listen: Your guide to Wegovy's blockbuster heart study

focus

entertainment

Wikipedia

knowledge

explore

focus

MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

The perfect storm of weather conditions that led to the devastating wildfires in Maui

AI models in health care face new federal disclosure requirements

White House drug shortages task force keeps mum with Congress

What causes an itch? Researchers may have solved the mystery

explore

focus

focus

Bright Health sells Medicare Advantage business to Molina

SCOTUS to consider access to abortion pill mifepristone

Medicare proposal to cover medical devices draws a mixed reaction

An innovative path out of biotech’s “valley of death”

Sports medicine is finally prioritizing gender equality

Congenital heart disease patients face new threat of heart failure

The cancer drug shortage isn’t new — and neither are the solutions

CMS should re

Psychedelics group wrestles with new pharma identity

Maui funeral service workers on devastation of fires: 'I'm in shock'

entertainment

Radiology is caught between AI's potential and concern for patients

SCOTUS to consider access to abortion pill mifepristone

Maui funeral service workers on devastation of fires: 'I'm in shock'

The history of OxyContin, told through Purdue Pharma documents

CDC overhauls leadership of center that led response to Covid

Genentech weighs delaying cancer therapy after drug pricing law

Wikipedia

knowledge

explore

focus